Across TCGA pan-cancer cohorts, TRAV3 Mutation is linked to patient survival in 4 of 34 cancer types, making it a survival-associated TRAV3 data layer compared with 21 for mass-spec protein.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where higher TRAV3 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated TRAV3 expression acts as an unfavorable survival marker, although some lineages such as SKCM show a favorable association.

HNSC, UCEC, and SKCM are the cancer types where TRAV3 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
HNSC	OS	Median	II,III,IV	0.156	0.743	.001	42	view →
UCEC	OS	Median	III,IV	0.061	0.588	.018	18	view →
SKCM	OS	Median	II,III,IV	0.973	0.720	.011	5	view →
BLCA	DFS	Median	IV	0.077	0.476	<.001	3	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

Exploration

Same gene, other analysis: TRAV3 tumor-vs-normal RNA expression · all TRAV3 data types